Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill

Executive Summary

Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.


Related Content

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Mercaptor Wants To Reinvent Drug Discovery And Development With No Pharma Or VC Funding
Biopharma Quarterly Dealmaking Statistics, Q3 2016
Post Depomed Deal Flop, Horizon Buys Crealta For $510m
Horizon Seeks Other Deals As Depomed Thwarts Takeover
Raptor Falls On Failed Investigator-Run NASH Study
Horizon Pharma signs $1.1bn deal to buy Hyperion
Horizon buying Vidara for Actimmune, Irish HQ


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts